bioAffinity Technologies, Inc. ((BIAF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. is spearheading a clinical study titled ‘Detection of Early-Stage Lung Cancer in Sputum Using Flow Cytometry and an Automated Analysis Pipeline.’ The study aims to assess the FlowPath Lung Diagnostic Test’s ability to detect lung cancer in high-risk individuals with existing lung nodules, sized between 6 to 30 mm, as determined by low-dose computed tomography (LDCT). This study is significant as it seeks to provide a non-invasive diagnostic method for early-stage lung cancer detection, potentially improving patient outcomes.
The intervention being tested is the FlowPath Lung Diagnostic Test, which involves diagnostic testing of sputum samples. This test is categorized as an ‘Other’ type intervention and is intended to serve as a sensitive and specific diagnostic tool for identifying lung cancer in high-risk individuals.
The study employs an interventional design with a single-group intervention model. There is no allocation or masking involved, and the primary purpose of the study is diagnostic. This straightforward design focuses on evaluating the diagnostic efficacy of the FlowPath Lung Test.
The study is currently not yet recruiting, with the first submission date recorded as September 5, 2025. This date marks the initiation of the study’s formal documentation process. The last update was also submitted on September 5, 2025, indicating the most recent information available.
From a market perspective, the successful development and validation of the FlowPath Lung Diagnostic Test could significantly impact bioAffinity Technologies’ stock performance. It may enhance investor sentiment by positioning the company as a leader in non-invasive cancer diagnostics. Additionally, advancements in this area could prompt competitive responses from other companies in the diagnostic industry, potentially influencing market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.